| Compound | AOD-9604 |
|---|---|
| Category | Modified HGH fragment |
| Class | Growth Hormone and Growth Factors |
| Evidence tier | Clinical-stage |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
This entry covers AOD-9604, a modified hgh fragment, graded "Clinical-stage" in this catalog's evidence system. This compound has completed or is undergoing formal human trials. Human safety and efficacy are being characterized, but no universal approval exists and results may still fail or be withdrawn.
A tyrosine-modified fragment of growth hormone (residues 177-191) developed as an anti-obesity drug candidate. It completed human trials but failed to demonstrate efficacy and was never approved.
Mechanism of Action
AOD-9604 was designed to isolate GH’s fat-regulating activity; preclinical lipolysis data motivated clinical obesity development.
Research and Evidence
Clinical development reached phase 2b in obesity, where it failed to separate from placebo on weight endpoints. It is the clearest cautionary tale for fragment-based fat-loss claims.
Safety and Side Effects
Human trials reported a tolerable short-term profile, but the failure of efficacy ended formal development. It appears on FDA compounding-watch lists.
Frequently Asked Questions
What is the evidence tier of AOD-9604?
AOD-9604 is graded "Clinical-stage" on this site. This compound has completed or is undergoing formal human trials. Human safety and efficacy are being characterized, but no universal approval exists and results may still fail or be withdrawn.
Is AOD-9604 an approved medicine?
No. Clinical-stage means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for AOD-9604?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — registered AOD-9604 studies. [source]
Evidence tier: Clinical-stage · Last reviewed: 2026-09-05 · Sources cited below.